Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
Sponsor: Yan Zhang, MD
Summary
This is a prospective, single-arm, phase II study, and the purpose of this study is to evaluate the efficacy and safety of Pola-R2 regimen in newly diagnosed elderly diffuse large B cell lymphoma classified into un-fit or frail group by comprehensive geriatric assessment(CGA).
Official title: A Prospective Phase II Study of Polatuzumab, Rituximab, and Lenalidomide(Pola-R2) in Newly-diagnosed Non-fit Elderly DLBCL Patients
Key Details
Gender
All
Age Range
70 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2023-10-24
Completion Date
2027-10-24
Last Updated
2023-12-20
Healthy Volunteers
No
Conditions
Interventions
Polatuzumab Vedotin, Rituximab, Lenalidomide
polatuzumab vedotin 1.8 mg/kg ivgtt D1, rituximab375 mg/m2 ivgtt D1, lenalidomide 25mg po D1-14, one cycle every 21 days
Locations (1)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China